Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Vaccinia Immune Globulin · Cnj-016, VIGIV

Plasma-derived product · Immune activation, directed at vaccinia virus · developed by Emergent Biosolutions Canada

Approved FDA, May 2005

EBS Developer

1 Registered trials

What is Vaccinia Immune Globulin?

VIGIV (vaccinia immune globulin intravenous, human) is a plasma-derived immune globulin that provides passive immunity against vaccinia virus complications.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Cnj-016, VIGIV
Drug type: Plasma-derived product
Targets: vaccinia virus
Mechanism: Immune activation, directed at vaccinia virus
Therapy area: Infectious disease
Developer: Emergent Biosolutions Canada Inc. (EBS)
FDA status: Approved as Cnj-016 (May 2, 2005), BLA125109 · FDA label
UNII: 7UB4J759TD

✅ FDA-approved uses

Eczema vaccinatum
Progressive vaccinia
Severe generalized vaccinia
Vaccinia infections in individuals with skin conditions
Aberrant infections induced by vaccinia virus

From the indications section of the FDA label (version of Dec 16, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01374984	N/A	Complication of Smallpox Vaccination	Enrolling by invitation	EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Complication of Smallpox Vaccination

More from Emergent Biosolutions Canada

AIGIV FDA approved Bacillus anthracis strain V770-NP1-R antigens FDA approved Brincidofovir FDA approved smallpox vaccine live, New York City Board of Health vaccinia strain FDA approved Ad4-EnvC150 Phase 1 Ad4-H5-Vtn Phase 1 Ad4-mgag Phase 1 Ad4-PA-1 Phase 1 Ad4-PA-GPI-1 Phase 1 AIDSVAX B/E Phase 1 AV7909 Phase 3 Botulinum Antitoxin Heptavalent Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.

Follow EBS, the company behind Vaccinia Immune Globulin

See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EBS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z